JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : BMB Reports
  • Volume 49, Issue 1,  2016, pp.63-68
  • Publisher : Korean Society for Biochemistry and Molecular Biology
  • DOI : 10.5483/BMBRep.2016.49.1.201
 Title & Authors
Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells
Park, Seohyun; Sim, Hyunsub; Lee, Keunwook;
  PDF(new window)
 Abstract
The serine/threonine kinase mTOR is essential for the phosphoinositide 3-kinases (PI3K) signaling pathway, and regulates the development and function of immune cells. Aberrant activation of mTOR signaling pathway is associated with many cancers including leukemia. Here, we report the contributions of mTOR signaling to growth of human leukemic cell lines and mouse T-cell acute leukemia (T-ALL) cells. Torin, an ATP-competitive mTOR inhibitor, was found to have both cytotoxic and cytostatic effects on U-937, THP-1, and RPMI-8226 cells, but not on Jurkat or K-562 cells. All cells were relatively resistant to rapamycin even with suppressed activity of mTOR complex 1. Growth of T-ALL cells induced by Notch1 was profoundly affected by torin partially due to increased expression of Bcl2l11 and Bbc3. Of note, activation of Akt or knockdown of FoxO1 mitigated the effect of mTOR inhibition on T-ALL cells. Our data provide insight on the effect of mTOR inhibitors on the survival and proliferation of leukemic cells, thus further improving our understanding on cell-context-dependent impacts of mTOR signaling. [BMB Reports 2016; 49(1): 63-68]
 Keywords
mTOR;torin;rapamycin;leukemic cell;T-ALL;
 Language
English
 Cited by
 References
1.
Powell JD, Pollizzi KN, Heikamp EB and Horton MR (2012) Regulation of immune responses by mTOR. Annu Rev Immunol 30, 39-68 crossref(new window)

2.
Laplante M and Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149, 274-293 crossref(new window)

3.
Zeng H and Chi H (2013) mTOR and lymphocyte metabolism. Curr Opin Immunol 25, 347-355 crossref(new window)

4.
Lee K, Gudapati P, Dragovic S et al (2010) Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 32, 743-753 crossref(new window)

5.
Lee K, Heffington L, Jellusova J et al (2013) Requirement for Rictor in homeostasis and function of mature B lymphoid cells. Blood 122, 2369-2379 crossref(new window)

6.
Lee K, Nam KT, Cho SH et al (2012) Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia. J Exp Med 209, 713-728 crossref(new window)

7.
Weichhart T, Hengstschlager M and Linke M (2015) Regulation of innate immune cell function by mTOR. Nat Rev Immunol 15, 599-614 crossref(new window)

8.
Hoshii T, Kasada A, Hatakeyama T et al (2014) Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells. Proc Natl Acad Sci U S A 111, 3805-3810 crossref(new window)

9.
Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9, 550-562 crossref(new window)

10.
Bertacchini J, Heidari N, Mediani L et al (2015) Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell Mol Life Sci 72, 2337-2347 crossref(new window)

11.
Tamburini J, Elie C, Bardet V et al (2007) Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 110, 1025-1028 crossref(new window)

12.
Silva A, Yunes JA, Cardoso BA et al (2008) PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118, 3762-3774 crossref(new window)

13.
Magee JA, Ikenoue T, Nakada D, Lee JY, Guan KL and Morrison SJ (2012) Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 11, 415-428 crossref(new window)

14.
Kalaitzidis D, Sykes SM, Wang Z et al (2012) mTOR complex 1 plays critical roles in hematopoiesis and Pten-lossevoked leukemogenesis. Cell Stem Cell 11, 429-439 crossref(new window)

15.
Xu Q, Thompson JE and Carroll M (2005) mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 106, 4261-4268 crossref(new window)

16.
Simioni C, Cani A, Martelli AM et al (2014) Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget 5, 10034-10047 crossref(new window)

17.
Wan X, Harkavy B, Shen N, Grohar P and Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26, 1932-1940 crossref(new window)

18.
Feldman ME, Apsel B, Uotila A et al (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7, e38 crossref(new window)

19.
Sarbassov DD, Ali SM, Sengupta S et al (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22, 159-168 crossref(new window)

20.
Badura S, Tesanovic T, Pfeifer H et al (2013) Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. PLoS One 8, e80070 crossref(new window)

21.
Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP and Baldwin AS (2008) Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 22, 1490-1500 crossref(new window)

22.
Wang P, Qiu W, Dudgeon C et al (2009) PUMA is directly activated by NF-kappaB and contributes to TNF-alpha-induced apoptosis. Cell Death Differ 16, 1192-1202 crossref(new window)

23.
Brunet A, Bonni A, Zigmond MJ et al (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868 crossref(new window)